KLH45
KLH45 Basic information
- Product Name:
- KLH45
- Synonyms:
-
- KLH45
- N-Cyclohexyl-N-(2-phenylethyl)-4-[4-(trifluoromethoxy)phenyl]-2H-1,2,3-triazole-2-carboxamide
- KLH45 >=98% (HPLC)
- 2H-1,2,3-Triazole-2-carboxamide, N-cyclohexyl-N-(2-phenylethyl)-4-[4-(trifluoromethoxy)phenyl]-
- KLH45, 10 mM in DMSO
- CAS:
- 1632236-44-2
- MF:
- C24H25F3N4O2
- MW:
- 458.48
- Mol File:
- 1632236-44-2.mol
KLH45 Chemical Properties
- Boiling point:
- 561.0±60.0 °C(Predicted)
- Density
- 1.29±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO:30.0(Max Conc. mg/mL);65.43(Max Conc. mM)
Ethanol:30.0(Max Conc. mg/mL);65.43(Max Conc. mM) - form
- Solid-Liquid Mixture
- pka
- -1.76±0.20(Predicted)
- color
- Off-white to light yellow
KLH45 Usage And Synthesis
Description
KLH45 is an inhibitor of the phospholipase DDHD domain containing 2 (DDHD2; IC50 = 1.3 nM). It is selective for DDHD2 over greater than 50 serine hydrolases, including DDHD1 and Sec23ip, but does inhibit α/β-hydrolase domain-containing protein 6 (ABHD6). It inhibits DDHD2 and ABHD6 in Neuro2A cells when used at a concentration of less than 10 nM and inhibits DDHD2 by greater than 95% at a concentration of 25 nM. KLH45 (2 μM) prevents increases in triacylglycerol (TAG) hydrolase activity in HEK293T cell lysates expressing recombinant DDHD2 and incubated with a radiolabeled TAG substrate. It decreases TAG levels in the CNS of mice when administered at a dose of 20 mg/kg twice per day for four days. KLH45 (2 μM) also reverses DDHD2-induced lipid droplet reduction in COS-7 cells expressing recombinant DDHD2 and loaded with oleic acid.
Uses
KLH45 is a novel selective inhibitor of DDHD2.
KLH45Supplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-52996696,15000506266 15000506266
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 17754423994 17754423994
- 2853530910@QQ.com
- Tel
- 400-9205774
- sales@glpbio.cn